Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pricing Debate

Set Alert for Pricing Debate

Sanofi/GSK Working With The US To Increase COVID-19 Vaccine Capacity

The $2.1bn investment under the US’ Operation Warp Speed will fund development, scale-up of US manufacturing and the first 100 million doses. 

Coronavirus COVID-19 Vaccines Pricing Strategies

Latest From Pricing Debate

WHO Launches Action Plan For Cross-Country Market Access Collaborations

While information sharing is key to cross-country collaborations on access to medicines and can lead to major benefits, it is hard to sell to political leaders and the media, says a report from the World Health Organization’s regional office for Europe.

Europe Legal Issues

Policies Targeting ‘Rebate Traps’ In Part D May Not Yield Big Savings, Study Suggests

Research on generic drug coverage in Medicare Part D plans finds access unobstructed for majority of lower cost alternatives. However, study may offer incomplete picture, generic and biosimilar advocates say.

Pricing Debate Regulation

Part D Demos: Insurer Participation In Insulin, Catastrophic Risk Sharing Models Varies Widely

Almost a third of Medicare drug plans are expected to offer the insulin demonstration next year, while almost none have signed up for the payment ‘modernization’ demo, under which plans would be at more risk for spending during the catastrophic phase. The Centers for Medicare and Medicaid Services also announces basic Part D premiums will average $30.50 for 2021.

Reimbursement Medicare

Moderna’s COVID-19 Vaccine Price Will Be Test of US Negotiating Power

Drug pricing experts are concerned the US government may not follow through on its commitment to pay less for COVID-19 vaccines it has helped fund given reports Moderna may be pushing a $50-$60/course price. The US also has little ability to control pricing in the private market – even for some government payers.

Coronavirus COVID-19 Vaccines

Biopharma, the White House And Getting Drug Pricing ‘Off The Table’

Industry balks at President Trump’s latest effort to force biopharma to negotiate a drug pricing solution, but investors may be pushing for concessions that could head off more onerous policies supported by a Biden White House. 

Pricing Debate Regulation

Opaque Pricing Could Protect Europe From US Policy

Obscure drug pricing in Europe could help minimize an “access threat” posed by US pricing policies.

Europe North America

Presidential Arm Twisting: Drug Pricing Order Would Advance International Benchmarks Unless Industry Offers Alternative

Industry has 30 days to come up with a better idea that would “end foreign free riding” and close the gap between drug prices in the US and abroad, President Trump says. Administration also wants to revive rebate reform.

Pricing Debate Policy & Regulation

Presidential Arm Twisting: Drug Pricing Order Would Advance International Benchmarks Unless Industry Offers Alternative

Industry has 30 days to come up with a better idea that would “end foreign free riding” and close the gap between drug prices in the US and abroad, President Trump says. Administration also wants to revive rebate reform.

Pricing Debate Policy & Regulation

Go Beyond The Vial: Medicare Policy Experts Urge Big Thinking On Drug Pricing

NASEM is expected to issue a highly anticipated report in early 2021 on solutions to address Rx vial drug wastage.

Medicare Pricing Debate
See All
UsernamePublicRestriction

Register